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Introduction
The most frequent foetal chromosomal abnormalities involve the autosomes 21, 18, 
13, and sex chromosomes X and Y. Aneuploidy or alterations in copy number of these 
chromosomes, including trisomy 21 (Down syndrome), trisomy 18 (Edwards’ syndrome), 
trisomy 13 (Patau’s syndrome), 45,X (Turner’s syndrome), and 47,XXY (Klinefelter’s 
syndrome) account for 80% of clinically significant chromosomal abnormalities diagnosed 
in the prenatal period. Down syndrome is a well-recognised cause of mental retardation, 
cardiac, and other congenital abnormalities. Edwards’ syndrome and Patau’s syndrome lead 
to multiple congenital abnormalities and early neonatal death. The phenotype of Turner’s 
	 Objectives	 The application of rapid aneuploidy testing as a stand-alone 
approach in prenatal diagnosis is much debated. The major 
criticism of this targeted approach is that it will not detect other 
chromosomal abnormalities that will be picked up by traditional 
karyotyping. This study aimed to study the nature of such 
chromosomal abnormalities and whether parents would choose 
to terminate affected pregnancies.
	 Design	 Retrospective study on a cytogenetic database.
	 Setting	 Eight public hospitals in Hong Kong.
	 Participants	 The karyotype results of 19 517 amniotic fluid cultures performed 
for advanced maternal age (≥35 years) from 1997 to 2002 were 
classified according to whether they were detectable by rapid 
aneuploidy testing. The outcomes of pregnancies with abnormal 
karyotypes were reviewed from patient records. 
	 Results	 In all,	 333 (1.7%) amniotic fluid cultures yielded abnormal 
karyotypes; 175 (52.6%) of these were detected by rapid 
aneuploidy testing, and included trisomy 21 (n=94, 28.2%), 
trisomy 18 or 13 (n=21, 6.3%), and sex chromosome abnormalities 
(n=60, 18.0%). The other 158 (47.4%) chromosomal abnormalities 
were not detectable by rapid aneuploidy testing, of which 63 
(18.9%) were regarded to be of potential clinical significance 
and 95 (28.5%) of no clinical significance. Pregnancy outcomes 
in 327/333 (98.2%) of these patients were retrieved. In total, 
143 (42.9%) of these pregnancies were terminated: 93/94 
(98.9%) for trisomy 21, 20/21 (95.2%) for trisomy 18 or 13, 19/60 
(31.7%) for sex chromosome abnormalities, and 11/63 (17.5%) 
for other chromosomal abnormalities with potential clinical 
significance. There were no terminations in the 95 pregnancies 
in which karyotyping results were regarded to be of no clinical 
significance.
	 Conclusions	 ‘Knowing less’ by the rapid aneuploidy stand-alone testing could 
miss about half of all chromosomal abnormalities detectable 
by amniocentesis performed for advanced maternal age. 
Findings from two fifths of the latter were of potential clinical 
significance, and the parents chose to terminate one out of six of 
the corresponding pregnancies. If both techniques are available, 
parents could have enhanced autonomy to choose.
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syndrome is highly variable and includes short 
stature, amenorrhoea, infertility, cardiac and renal 
malformations. Klinefelter’s syndrome is associated 
with a relatively mild phenotype abnormality.
 The traditional method for prenatal diagnosis 
of these common aneuploidies involves analysis of 
banded metaphase chromosomes from cultured 
amniotic fluid cells (amniocentesis) or chorionic 
villi (chorionic villus sampling). It is known as 
karyotyping, for which all 23 pairs of chromosomes 
are examined. Apart from the common aneuploidies, 
a wide range of chromosomal abnormalities can 
thus be identified by this technique, including 
rearrangements, such as translocations and inversions 
that may be balanced or unbalanced. Traditional 
karyotyping is labour-intensive and the results are 
usually not available for 2 weeks or more. Advances 
in molecular diagnostics, using either fluorescence 
in situ hybridisation (FISH1-5) with chromosome-
specific DNA probes or quantitative fluorescence–
polymerase chain reaction (QF-PCR6-11) with 
chromosome-specific small tandem repeat markers, 
can be applied to diagnose the common aneuploidies 
within 1 to 2 days. The sensitivity and specificity of 
FISH and QF-PCR, collectively described as rapid 
aneuploidy testing (RAT), have been demonstrated in 
the aforementioned studies and compare favourably 
with traditional karyotyping for the diagnosis of the 
common aneuploidies. Unlike karyotyping, these 
technologies only allow the identification of the 
chromosomal abnormalities that are specifically 
sought (targeted testing).
 Currently, RAT (FISH or QF-PCR) is being used 
to give a rapid result for the common aneuploidies as 
an adjunct to karyotyping. This combined approach 
clearly increases the cost of prenatal diagnosis. 
It has been suggested that if the indication for 
prenatal diagnosis is an increased risk of Down 
syndrome arising from a positive screening test 
result or advanced maternal age, then karyotyping 
could be replaced by RAT.9,12-17 This new approach 
has been challenged, because certain chromosomal 
abnormalities, although infrequent and usually 
of debatable significance, would be missed,5,18-20 
which has resulted in much debate in this area of 
prenatal diagnosis. For example, initiatives by the 
UK Government21 to replace traditional karyotyping 
with new screening programmes involving RAT, FISH, 
and QF-PCR, were objected by the UK Association 
of Clinical Cytogeneticists (ACC). Caine et al22 from 
the ACC undertook a retrospective cytogenetic audit 
on 119 528 amniotic fluid and 23 077 chorionic villus 
samples from 1999 to 2004 to assess the probable 
clinical impact of these proposed policy changes. They 
showed that about 1% of all prenatal samples would 
have a chromosomal abnormality undetected by RAT 
and that a third of these might have a significant risk 
of serious phenotypic consequences if RAT was used 
alone.22 However, these workers had not addressed 
two important issues relevant to the debate on 
RAT versus traditional karyotyping.23 The first was 
the role of ultrasound examination for structural 
abnormalities in the foetus. A recent prospective 
study on 1589 amniocenteses samples obtained 
for various indications showed that 69% (9/13) of 
clinically significant chromosomal abnormalities not 
detectable by RAT had foetal abnormalities detected 
by ultrasound.24 Kagan et al25 had recently shown that 
more than 98% of all chromosomal abnormalities 
can be detected if QF-PCR was	 performed in all 
samples and karyotyping	in about 16% of the samples	
selected on the basis of ultrasound findings before 
amniocentesis. The second issue is the clinical 
outcome of chromosomal abnormalities that are not 
detectable by the RAT stand-alone approach.23 The 
clinical significance of the latter, particularly those 
without ultrasound-detected foetal abnormalities, 
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is very different from that of trisomy 21, 18, or 13.26 
Prenatal identification of this group of chromosomal 
abnormalities often poses difficult counselling 
issues, as termination of pregnancy (TOP) may be 
unnecessary and not in the best interests of the 
parents or the foetus. Here we try to identify the 
nature of the chromosomal abnormalities from a 
cohort of pregnancies with amniocenteses performed 
for advanced maternal age and whether the parents 
would choose TOP.
Methods
This study utilised the database of the Prenatal 
Diagnostic Laboratory, at Tsan Yuk Hospital, which 
receives all the prenatal samples from eight public 
hospitals in Hong Kong. The results were sent to the 
referring hospitals for further action. If necessary, 
the parents were counselled on the chromosomal 
abnormalities, mainly by obstetricians in the 
individual hospital, and in some cases with the help 
of paediatricians and geneticists. In this database, 
the indications for amniocentesis were categorised 
in a hierarchical fashion as follows: (1) ultrasound-
detected foetal abnormalities, (2) positive Down 
syndrome screening, (3) advanced maternal age 
(≥35 years old), and (4) other indications. If one or 
more ultrasound-detected foetal abnormalities were 
reported, the case was classified as having ultrasound-
detected abnormalities (1); this was irrespective of 
the Down syndrome screening result or maternal 
age. If amniocentesis was performed for positive 
Down screening in a woman aged 35 years or above, 
the case was classified as (2). We retrospectively 
reviewed the results of 19 517 amniotic fluid cultures 
performed specifically for advanced maternal age 
(3) from 1997 to 2002. Within the same period, there 
were 1061 amniotic fluid cultures performed for 
ultrasound-detected foetal abnormalities, 1629 for 
Down syndrome screening and 2039 cultures for 
other indications.
 The results were categorised into normal and 
abnormal karyotypes. Abnormal karyotypes were 
divided into common aneuplodies of chromosomes 21, 
18, 13, X and Y, and other chromosomal abnormalities. 
The latter were further subdivided into a group with 
potential clinical significance (de-novo balanced 
translocations and chromosomal rearrangements, 
unbalanced translocations and chromosomal 
rearrangements, uncommon autosomal trisomies, 
de-novo markers) and another group with no clinical 
significance (balanced translocations/chromosomal 
rearrangements/markers of familial origin, de-novo 
balanced Robertsonian translocations). A second 
classification was performed on whether the 
results were detectable by RAT. The outcomes of 
these pregnancies with abnormal karyotypes were 
reviewed from patient records in each hospital, 
through our Working Group on Prenatal Diagnosis 
and Counselling.
Results
The results of karyotyping of 19 517 amniotic fluid 
cultures performed for advanced maternal age from 
1997 to 2002 are shown in the Figure. There were 333 
(1.7%) abnormal karyotypes. Among these, 175 (53%) 
were common aneuploidies detectable by RAT. The 
other 158 (47%) were not detectable by RAT. The latter 
were further subdivided into 63 (19%) with potential 
clinical significance and 95 (29%) with no clinical 
significance.
 We obtained the pregnancy outcomes in 
327/333 (98.2%) of these patients (Tables 1-3). In 
total, 143 (43%) pregnancies were terminated; 93/94 
(99%) trisomy 21, 20/21 (95%) trisomy 18 or 13, 19/60 
(32%) sex chromosome abnormalities, 11/63 (18%) 
other chromosomal abnormalities with potential 
clinical significance, and 0/95 (0%) with no clinical 
significance.
 Terminations of pregnancy were separated 
into two groups. In group 1, they were performed 
due to major chromosomal abnormalities or major 
ultrasound-detected structural foetal abnormalities. 
Major chromosomal abnormalities referred to trisomy 
21, 18 and 13 (Table 1), and one case of 5p- or cri-du-
chat syndrome (Table 2). Four others of potential 
clinical significance were terminated because of 
structural foetal abnormalities detected subsequently 
by ultrasound examination. They included cleft lip 
and palate, micrognathia, clinodactyly, microcephaly, 
aortic stenosis (Table 2). In group 2, although the 
chromosomal abnormalities were not major and 
no ultrasound-detected foetal abnormalities were 
present, the parents could not accept the uncertainty 
in clinical outcome, which varied from normal to 
a degree of mental impairment and/or physical 
abnormality that might not even be evident at birth. 
Certain sex chromosome abnormalities were also 
considered under this category.
 Table 4 shows the details of the 143 cases with 
chromosomal abnormalities among those undergoing 
TOP, of which 25 (18%) belonged to group 2.
Discussion
The clinical application of RAT as a stand-alone 
approach in prenatal diagnosis is subject to much 
debate. The pros and cons of this approach have been 
discussed in recent review articles.17,27-31 The major 
criticism is that such targeted testing would miss 
the diagnosis of certain chromosomal abnormalities 
that will be picked up by traditional karyotyping. The 
counter argument is that 60% of these abnormalities 
are not clinically significant, and the other 40% are 
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only of potential clinical significance (excluding 
those with major ultrasound-detected structural 
abnormalities in the foetus).23
 The feasibility of the RAT stand-alone approach 
depends on the indication for the invasive prenatal 
test. With the presence of major ultrasound-detected 
foetal abnormalities, traditional karyotyping should 
be performed to look for structural chromosomal 
abnormalities apart from aneuploidies.13,24,32 The 
RAT stand-alone approach is best when the invasive 
prenatal test is performed for an identified increased 
risk of Down syndrome from a positive Down 
screening test. We have previously demonstrated 
the feasibility of this approach in 1526 cases, with 
amniocenteses performed for positive biochemical 
Down screening.15 For the present study, we chose 
the much larger dataset of amniocenteses (19 517 
cases) performed specifically for advanced maternal 
age, focusing on the pregnancy outcomes of the 333 
cases with chromosomal abnormalities.
 As expected, the great majority (98.3%) of 
amniocenteses performed for advanced maternal 
age showed normal results (Fig 1). For this large 
group of parents, RAT could exclude the possibility 
of foetal Down syndrome and relieve anxiety within 
1 to 2 days of amniocentesis.33 To supplement this 
Chromosomal abnormality TOP† TOP‡ Livebirth with no 
abnormality
Unknown 
outcome
Total
Trisomy 21 93 1 (mosaic) 94
Trisomy 18 15 15
Trisomy 13 5 1 (mosaic) 6
Sex chromosome abnormalities 19 40 1 60
Mosaic Turner’s syndrome 5 11 16
Sex chromosome polysomies (mosaic) 12 (1) 29 (5) 1 42 (6)
Structural X chromosome abnormalities 2 2
Total 113 19 42 1 175
TABLE 1. Pregnancy outcomes of common aneuploidies detectable by rapid aneuploidy testing (RAT)*
* TOP denotes termination of pregnancy; the detection of mosaic aneuploidies by RAT depends on the % of mosaicism present; the 
detection of structural X chromosome abnormalities by RAT depends on the nature of probes (fluorescence in situ hybridisation) or 
markers (quantitative fluorescence–polymerase chain reaction) used
† TOP for major chromosomal abnormalities
‡ TOP in the absence of major chromosomal abnormalities or major ultrasound-detected structural foetal abnormalities
FIG. Traditional karyotyping results of amniocenteses performed for advanced maternal age from 1997 to 2002
RAT denotes rapid aneuploidy testing
Table 1
Table 2Table 3
19 517 amniotic fluid cultures
19 184 (98.3%) Normal 
karyotypes (detectable by 
RAT)
158 (47.4%) Other 
chromosomal abnormalities 
(not detectable by RAT)
175 (52.6%) Common aneuploidies 
(detectable by RAT)
• Trisomy 21 (n=94, 28.2%)
• Trisomy 18 (n=15)
• Trisomy 13 (n=6)
• Sex chromosome abnormalities 
(n=60, 18.0%)
95 (28.5%) 
with no clinical 
significance 
63 (18.9%) 
with potential 
clinical 
significance 
6.3%
333 (1.7%) Abnormal 
karyotypes 
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fast report with the traditional karyotyping (whose 
results become available) in 2 to 3 weeks seems 
unnecessary.
 The pregnancy outcomes of the various 
common aneuploidies detectable by RAT could be 
very different (Table 1). Essentially, all cases with 
non-mosaic trisomies 21, 18 and 13 were terminated. 
If RAT was performed, the decision to terminate the 
pregnancies could be made 2 to 3 weeks earlier.34 
On the other hand, sex chromosome abnormalities 
pertained to another issue (Table 1). None of them had 
major ultrasound-detected foetal abnormalities in this 
dataset of amniocenteses performed for advanced 
maternal age. Two thirds of the parents decided to 
continue with the pregnancies, which resulted in 
livebirths with no morphological abnormality at 
birth, while the other third decided to terminate 
the pregnancies. Not surprisingly the prognosis 
of persons with sex chromosome abnormalities is 
very different from that of trisomies 21, 18 and 13. 
Thus, some obstetricians, clinical geneticists, and 
genetic counsellors are uneasy about testing and 
reporting the sex chromosome status of all foetuses 
undergoing invasive prenatal tests.35-37 Identification 
of sex chromosome abnormalities such as XXX, XYY 
and XXY (Klinefelter’s syndrome), that are either 
asymptomatic or associated with a relatively mild 
phenotype, often poses difficult counselling issues 
and may not be in the best interests of the parents. 
Such findings tend to increase parental anxiety and 
present a difficult choice regarding the continuation 
of the pregnancy. On the other hand, the Turner’s 
syndrome (45,X) phenotype is highly variable with 
respect to short stature, amenorrhoea, infertility, 
cardiac malformations (coarctation of aorta) and renal 
complications.38 Besides, up to 99% of foetuses with 
Turner’s syndrome are miscarried during the first and 
second trimester of pregnancy,39 and those that do 
not miscarry usually have ultrasound abnormalities.40 
Donaghue et al37 has proposed a selective policy for 
foetal sexing if RAT is to be used as a stand-alone 
test. Aneuploidies of X and Y chromosomes will be 
determined by RAT only in cases displaying ultrasound 
abnormalities consistent with Turner’s syndrome and 
those at risk of inheriting a sex-linked disorder. The 
ultrasound findings in Turner’s syndrome include: 
cystic hygroma, nuchal thickening of 5 mm or more, 
adjusted nuchal risk of 1:5 or higher, hydrops, nuchal 
oedema or coarctation of the aorta.37 This targeting 
policy for sex chromosome tests may avoid the 
unintentional finding of conditions of borderline 
significance, such as XXX, XYY and XXY, during 
prenatal testing for Down syndrome.
 When amniocenteses were performed for 
advanced maternal age, chromosomal abnormalities 
not detectable by RAT (Tables 2 and 3) were unexpected 
by the couples as well as the obstetricians.41 They 
would have been excluded from prenatal testing, if RAT 
Chromosomal abnormality TOP TOP§ Livebirth with no 
abnormality
Other 
outcome
Unknown 
outcome
Total
Balanced translocations (de novo) 1 19 1 miscarriage 1 22
Balanced chromosomal rearrangements (de novo) 17 17
Unbalanced translocations 1‡ 1
Unbalanced chromosomal rearrangements 1† 4 1 1 miscarriage 7
Other autosomal trisomies 2‡ (mosaic) 3 (mosaic) 1 6
Markers (de novo) 1‡ 1 (mosaic) 6 1 livebirth with 
abnormality
1 10
Total 5 6 46 3 3 63
TABLE 2. Pregnancy outcomes of chromosomal abnormalities with potential clinical significance not detectable by rapid aneuploidy testing*
* TOP denotes termination of pregnancy
† TOP for major chromosomal abnormalities
‡ TOP for major ultrasound-detected structural foetal abnormalities
§ TOP in the absence of major chromosomal abnormalities or major ultrasound-detected structural foetal abnormalities
Chromosomal abnormality TOP Livebirth with no 
abnormality
Other outcome Unknown 
outcome
Total
Balanced translocations, chromosomal 
rearrangements, markers of familial origin
86 1 livebirth with abnormality
1 intra-uterine death
2 90
Balanced Robertsonian translocations (de novo) 5 5
Total 91 2 2 95
TABLE 3. Pregnancy outcomes of chromosomal abnormalities with no clinical significance not detectable by rapid aneuploidy testing*
* TOP denotes termination of pregnancy
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Chromosomal abnormality No. with TOP Details of chromosomal abnormalities with TOP No.
Common autosomal aneuploidies 113/115 (98.3%) Trisomy 21 93
Trisomy 18 15
Trisomy 13 5
Mosaic Turner’s syndrome 5/16 (31.3%) 45,X[7]/46,XX [40] 1*
45,X[16]/46,XX [14] 1*
45,X[2]/47,XXX[6]/46,XX [45] 1*
45,X[5]/47,XXX[15]/46,XX [40] 1*
45,X,inv(9)(p11q13)[13]/46,X,i(X)(q10),inv(9)(p11q13) [47] 1*
Sex chromosome polysomies 12/42 (28.6%) 47,XXY 9*
47,XYY[19]/46,XY [31] 1*
47,XXX 2*
Structural X chromosome abnormalities 2/2 (100%) 46,X,Xp- 1*
46,X,i(X)(q10) 1*
Balanced translocations (de novo) 1/22 (4.5%) 46,XX,t(2;13)(q32;q21)de novo 1*
Unbalanced translocations 1/1 (100%) 46,XX,der(10)t(10;22)(q26.1;q11.2)pat 1
Unbalanced chromosomal rearrangements 5/7 (71.4%) 46,XX,2p+ de novo 1*
46,XY,11q-,13q- de novo 1*
46,XY,5p- de novo 1
46,XY,5p+ de novo 1*
46,XY,9p+ de novo 1*
Other autosomal trisomies 2/6 (33.3%) 47,XX,+20[14]/46,XX [26] 1
47,XX,+9[47]/46,XX [53] 1
Markers (de novo) 2/10 (20.0%) 47,XY,+mar de novo 1
47,XY,+mar[14]/46,XY [47] 1*
Total 143 (25*)
TABLE 4. Chromosomal abnormalities with termination of pregnancy (TOP)
* TOP in the absence of major chromosomal abnormalities or major ultrasound-detected structural foetal abnormalities
were applied as a stand-alone test in the absence of 
ultrasound-detected structural foetal abnormalities. 
Some of them had potential clinical significance 
(Table 2) while others had no clinical significance 
(Table 3). For those chromosomal abnormalities with 
potential clinical significance (Table 2), 49 couples 
decided to continue with the pregnancies. Eleven 
couples decided to terminate the pregnancies: 
four owing to the presence of foetal abnormalities 
(cleft lip and palate, micrognathia, clinodactyly, 
microcephaly, aortic stenosis), which were discovered 
during subsequent ultrasound examinations after 
the chromosomal abnormalities were identified (ie 
group 1, Table 2). One termination was for 5p- (cri-
du-chat) syndrome and the other six because the 
parents could not accept the uncertainty in clinical 
outcome varying from normal to a certain degree 
of mental impairment and physical abnormalities, 
which might not be diagnosed even at birth (ie group 
2, Table 2).42 So, what might ensue if RAT is replaced 
by traditional karyotyping? The 5p- syndrome would 
be missed. The other six chromosomal abnormalities 
with potential clinical significance would not be 
diagnosed and the respective parents would not have 
the chance to consider TOP.
 For chromosomal abnormalities with no clinical 
significance (Table 3), karyotyping provided no useful 
additional information (except that the finding of a 
familial translocation will have implications for future 
pregnancies). Instead it led to additional counselling 
time to convey information and to relieve parental 
anxiety. None of these 95 cases had TOP.
 Overall, 143 pregnancies were terminated, 25 
(17.5%) of them belonged to the group in which the 
chromosomal abnormalities were not major (19 sex 
chromosome abnormalities and six chromosomal 
abnormalities with potential clinical significance) and 
there were no major ultrasound-detected structural 
foetal abnormalities (Table 4). If RAT (for trisomies 
21, 18 and 13 only) had been used as a stand-alone 
approach, it could have been coupled with RAT 
testing for sex chromosome aneuploidies only when 
ultrasound-detected abnormalities were consistent 
with Turner’s syndrome.37 In which case, traditional 
karyotyping would only be needed when there 
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were major ultrasound-detected structural foetal 
abnormalities,13,24,32 and consequently the 25 cases 
without major abnormalities would not be diagnosed 
and the parents would not have the option to 
terminate these pregnancies. One might argue that 
this is a beneficence-based approach (the physician 
making decisions that are best for the patient, without 
regard to personal gain or the interests of others). 
Some of these 25 TOP were probably unnecessary 
because the chromosomal abnormalities are only 
of potential clinical significance, particularly in the 
absence of ultrasound-detected foetal abnormalities. 
On the other hand, the ethics of prenatal diagnosis 
should be autonomy-based (the capacity of a rational 
individual to make an informed, uncoerced decision; 
in medicine, respect for the autonomy of patients is 
considered obligatory for doctors and other health 
care professionals). If the parents choose to have 
TOP for minor chromosomal abnormalities, we have 
the obligation to make sure that the counselling is 
thorough, to ensure that they have the information 
about the outcomes in order to exercise their 
autonomy to continue or terminate the pregnancy. 
If after that process, the parents still choose to 
terminate the pregnancy, then their decision and 
autonomy must be respected. A medical attitude of 
“we will not look for sex chromosome abnormalities 
and other minor chromosomal abnormalities as we 
do not consider you should have a termination” 
could be considered paternalistic (a figurehead that 
makes decisions on behalf of others for their own 
good, even if this is contrary to their wishes). If both 
techniques are available, parents should have the 
autonomy to choose the approach (RAT, or traditional 
karyotyping, or both) after being fully informed 
of the pros and cons. Bui43 recently reported their 
experience in Stockholm, when Swedish women were 
given this choice, 70% of them chose the RAT stand-
alone approach.43 It would be interesting to study 
the parental preference in our Chinese population, 
particularly in Mainland China, which operates a 
one-child policy.
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